APN News

RSSDI gets nominated for the prestigious IDF Centenary of Insulin Award at the World Diabetes Congress

New Delhi : To recognize the outstanding effort of enhancing the lives of people with diabetes, the International Diabetes Federation (IDF) at World Diabetes Congress in Lisbon, Portugal (5-8 December) will present the IDF Centenary of Insulin Award. Research Society for the Study of Diabetes in India (RSSDI), New Delhi, has been nominated for the award at the global platform due to the profound success of its Defeat Diabetes Campaign that was launched on 1 July 2022(Doctors Day) with the objective of reaching 100 million people in 100 days with the message – Test, Track, and Treat. 

The expert panel from the International Diabetes Federation (IDF) will select a winner from the nominees across the world. The winner will receive a grant of EUR 25,000 to continue the exceptional work. The selection criteria for the nominees included outstanding contributions to diabetes over the past three years. Dr Rakesh Parikh and Dr Amit Gupta will be presenting the data at the IDF World Diabetes Congress and Dr. BM Makkar, Dr. Sanjay Agarwal, and Dr. Banshi Saboo will represent the RSSDI at the global forum.

Sharing his thoughts on this achievement, Dr. Sanjay Agarwal, Secy General of RSSDI,  said “We are elated to have been nominated for the award. We have been consistently thriving towards researching and spreading awareness about diabetes among the masses. Receiving international recognition for creating an impact through our work will motivate us all the more so to stay focussed in the right direction.” 

The IDF Centenary of Insulin Award winner will be invited to give a brief presentation about the award-winning initiative during a ceremony on Wednesday, 7 December at 4:30 pm in Auditorium VI, VII of the Centro de Congressos de Lisboa CCL.

The event will be an enlightening and interactive opportunity for the nominated organizations to exhibit their contribution to the global diabetes community. This campaign, called the insulin at 100, is supported by pharmaceutical giants — Gan & Lee, Lilly Diabetes, and Sanofi. 

Exit mobile version